benzoic acid N'-(3-hydroxynaphthalene-2-carbonyl)hydrazide | 124843-39-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: benzoic acid N'-(3-hydroxynaphthalene-2-carbonyl)hydrazide
• 英文别名: N'-phenacyl-3-hydroxy-2-naphthoylhydrazide；N-benzoyl-N'-(3-hydroxy-[2]naphthoyl)-hydrazine；N-Benzoyl-N'-(3-hydroxy-[2]naphthoyl)-hydrazin；3-Oxy-naphthoesaeure-(2)-benzoylhydrazid；3-hydroxy-N'-phenylnaphthalene-2-carbohydrazide；N'-benzoyl-3-hydroxynaphthalene-2-carbohydrazide
• CAS: 124843-39-6
• 化学式: C₁₈H₁₄N₂O₃
• 分子量: 306.321
• InChiKey: NQJRHDOJHKPKKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 benzoic acid N'-(3-hydroxynaphthalene-2-carbonyl)hydrazide 、 manganese (II) acetate tetrahydrate 、 N,N-二甲基甲酰胺 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 以18.9%的产率得到[Mn10(N'-phenacyl-3-oxy-2-naphthoylhydrazide)10(dimethylformamide)4(H2O)6]-dimethylformamide-methanol-water (1/1/10.5)
  参考文献：
  名称：

  两种锰金属冠的合成、表征和晶体结构：30-Metallacrown-10 和 18-Metallacrown-6 配体衍生自 3-Hydroxy-2-naphthalenecarbohydrazide

  摘要：

  两种锰金属冠[Mn10(pnhz)10(DMF)4(H2O)6]·10.5H2O·MeOH·DMF(1)和[Mn6(anhz)6(DMF)2(H2O)4]·6DMF(2)， (H3pnhz = 3-hydroxy-N-phenyl-2-naphthalenecarbohydrazide, H3anhz = N-acyl-3-hydroxy-2-naphthalenecarbohydrazide) 是通过两个五齿配体 H3anhz 和 H3pnhz 与相应的锰 (II) 反应制备的) 盐，分别通过元素分析、红外光谱和 X 射线单晶衍射分析进行表征。配合物1具有[Mn-N-N]10骨架，两种MnIII中心呈···AABAB···排列，金属中心呈···ΔΛΔΛ···手性构型排列。相邻分子通过四个分子间H键连接形成一维无限链结构。这是第一个由弱相互作用形成的金属冠的一维超分子样品。复合物 2 显示了一个

  DOI：

  10.1002/ejic.200600565
• 作为产物：
  描述：

  3-羟基-2-萘甲酸甲酯 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 生成 benzoic acid N'-(3-hydroxynaphthalene-2-carbonyl)hydrazide
  参考文献：
  名称：

  酰肼类衍生物及其应用

  摘要：

  本发明提供一种酰肼类衍生物及其药学上可接受的盐，通过化学合成得到，药理实验证明所述化合物具有抗肿瘤细胞增殖的活性，并且部分化合物展现出了抑制DJ‑1蛋白二聚化的活性，可用于制备治疗、预防和抑制与DJ‑1相关的肿瘤、Ⅱ型糖尿病、帕金森病和阿尔兹海默病等神经退行性疾病的药物。所述化合物结构通式Ⅰ为：

  公开号：

  CN108329232B

文献信息

• Rubber composition and pneumatic tires
  申请人：Bridgestone Corporation

  公开号：US06380288B1

  公开（公告）日：2002-04-30

  A rubber composition prepared by compounding 0.05 to 20 parts by weight of at least one selected from substituted hydrazide compounds represented by the following Formulas (I) to (IV) per 100 parts by weight of a rubber component comprising at least one rubber selected from the group consisting of natural rubber and synthetic rubber, and a pneumatic tire using the same: wherein A represents one selected from the group consisting of an aromatic group which may have a substituent, a hydantoin ring which may have a substituent, and a saturated or unsaturated linear hydrocarbon having 1 to 18 carbon atoms; Y represents hydrogen, an amino group, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group, an alkenyl group, an aromatic group, a pyridyl group or hydrazino group; and R1 to R11 each represent hydrogen, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group or an aromatic group.

  一种橡胶组合物，其通过将以下式子（I）到（IV）中的至少一种取代肼化合物的0.05至20重量份与至少一种天然橡胶或合成橡胶组成的橡胶组分的100重量份混合制备而成，其中A表示选自芳香族基团，该基团可能带有取代基，咪唑环，该环可能带有取代基，以及具有1至18个碳原子的饱和或不饱和线性碳氢化合物中的一种；Y表示氢，氨基，具有1至18个碳原子的烷基，环烷基，烯基，芳香族基团，吡啶基或肼基；R1到R11分别表示氢，具有1至18个碳原子的烷基，环烷基或芳香族基团。并且使用该橡胶组合物制备的气动轮胎。
• NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION
  申请人：Neamati Nouri

  公开号：US20090093489A1

  公开（公告）日：2009-04-09

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法、含有这些化合物的药物组合物和包装产品、使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法、监测治疗的方法、基因表达谱分析的方法以及调节细胞生长、细胞周期、细胞凋亡或基因表达的方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function
  申请人：Neamati Nouri

  公开号：US20100120781A1

  公开（公告）日：2010-05-13

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  该专利涉及新型化合物，用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及细胞生长、细胞周期、凋亡或基因表达的调节方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
  申请人：NEAMATI Nouri

  公开号：US20110034472A1

  公开（公告）日：2011-02-10

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及调节细胞生长、细胞周期、凋亡或基因表达的方法。
• RUBBER COMPOSITION AND PNEUMATIC TIRES
  申请人：Bridgestone Corporation

  公开号：EP0909788A1

  公开（公告）日：1999-04-21

  A rubber composition prepared by compounding 0.05 to 20 parts by weight of at least one selected from substituted hydrazide compounds represented by the following Formulas (I) to (IV) per 100 parts by weight of a rubber component comprising at least one rubber selected from the group consisting of natural rubber and synthetic rubber, and a pneumatic tire using the same: wherein A represents one selected from the group consisting of an aromatic group which may have a substituent, a hydantoin ring which may have a substituent, and a saturated or unsaturated linear hydrocarbon having 1 to 18 carbon atoms; Y represents hydrogen, an amino group, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group, an alkenyl group, an aromatic group, a pyridyl group or hydrazino group; and R1 to R11 each represent hydrogen, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group or an aromatic group.

  一种橡胶组合物，其制备方法是每 100 重量份由至少一种选自天然橡胶和合成橡胶组的橡胶组成的橡胶组分中混入 0.05 至 20 重量份的至少一种选自下式(I)至(IV)所代表的取代酰肼化合物，以及使用该组合物的充气轮胎： 其中 A 代表选自芳香基团（可具有取代基）、海因环（可具有取代基）和具有 1 至 18 个碳原子的饱和或不饱和线性烃；Y 代表氢、氨基、具有 1 至 18 个碳原子的烷基、环烷基、烯基、芳香基、吡啶基或肼基；R1 至 R11 分别代表氢、具有 1 至 18 个碳原子的烷基、环烷基或芳香基。